Topics

Crescita Therapeutics Signs Pliaglis Out-Licensing Agreement with Cantabria Labs

13:12 EDT 1 May 2019 | Proactive Investors

Crescita Therapeutics (TSE:CTX-OTC:CFFTF) President and CEO Serge Verreault joined Steve Darling from Proactive Investors Vancouver to discuss the dermatology company signing a big deal with Cantabria Labs for their product Pliaglis. 

Verreault telling Proactive how much that is worth to the company and which markets the deal opens up.

Original Article: Crescita Therapeutics Signs Pliaglis Out-Licensing Agreement with Cantabria Labs

NEXT ARTICLE

More From BioPortfolio on "Crescita Therapeutics Signs Pliaglis Out-Licensing Agreement with Cantabria Labs"

Quick Search

Relevant Topic

Dermatology
Acne Dermatology Eczema Psoriasis Wound Care Dermatology is the medical specialty concerned with the diagnosis and treatment of skin disorders (Oxford Medical Dictionary). As well as studying how the skin works, dermatology covers...